Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

被引：0
|
作者：
Felip, Enriqueta
Doger, Bernard
Majem, Margarita
Carcereny, Enric
Krebs, Matthew
Peguero, Julio Antonio
Roxburgh, Patricia
Forster, Martin
Bajaj, Pawan
Clay, Timothy Dudley
Triebel, Frederic
机构：
[1] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[3] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[4] Hosp Badalona Germans Trias & Pujol, B ARGO Grp Badalona Appl Res Grp Oncol, Catalan Inst Oncol, Med Oncol Dept, Badalona, Spain
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[7] Oncol Consultants PA, Dept Res, Houston, TX USA
[8] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[9] UCL Canc Inst, London, England
[10] Univ Coll London Hosp, London, England
[11] Griffith Univ, Brisbane, Qld, Australia
[12] St John God Hosp, Perth, WA, Australia
[13] Immutep, Res & Dev, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3100
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
    Clay, Timothy Dudley
    Majem, Margarita
    Felip, Enriqueta
    Doger, Bernard
    Costa, Enric Carcereny
    Forster, Martin
    Krebs, Matthew
    Peguero, Julio Antonio
    Mueller, Christian
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [12] TACTI-003: A RANDOMIZED PHASE IIB STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB AS FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Brana, Irene
    Cheshuk, Valerii
    Kristensen, Claus Andrup
    Eugenia Ortega, Maria
    Sautois, Brieuc
    Lopez-Pousa, Antonio
    Christian, Judith
    Lybaert, Willem
    Peguero, Julio
    Park, John
    Metcalf, Robert
    Nabell, Lisle
    Doger de Speville, Bernard
    Rubio Casadevall, Jordi
    Soria Rivas, Ainara
    Forster, Martin
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A705 - A705
  • [13] TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
    Forster, M.
    Krebs, M.
    Majem, M.
    Peguero, J.
    Clay, T.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    Doger, B.
    Bajaj, P.
    Kefas, J.
    Scott, J. A.
    Joaquin, A. Barba
    Mueller, C.
    Triebel, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S395 - S395
  • [14] TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Adkins, Douglas
    Cheshuk, Valerii
    Peguero, Julio Antonio
    Park, John J.
    Lopez-Pousa, Antonio
    Lybaert, Willem
    Brana, Irene
    Doger, Bernard
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
    Brana, Irene
    Forster, Martin
    Lopez-Pousa, Antonio
    Doger, Bernard
    Roxburgh, Patricia
    Bajaj, Pawan
    Portillo, Daniela Urueta
    Quiroga, Vanesa
    Krebs, Matthew
    Mueller, Christian
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [16] RESULTS FROM A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS WITH PD-L1 UNSELECTED METASTATIC 2ND LINE HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Pousa, Antonio Lopez
    Felip, Enriqueta
    Forster, Martin
    Doger, Bernard
    Roxburgh, Patricia
    Bajaj, Pawan
    Peguero, Julio
    Carcereny, Enric
    Krebs, Matthew
    Mueller, Christian
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A386 - A386
  • [17] A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS UNSELECTED FOR PD-L1 EXPRESSION IN FIRST LINE METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Peguero, Julio
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A470 - A470
  • [18] Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
    Krebs, M. G.
    Tarruella, M. Majem
    Forster, M.
    Peguero, J. A.
    Clay, T.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    de Speville, B. Doger
    Bajaj, P.
    Mueller, C.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S33 - S33
  • [19] Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
    Majem, M.
    Forster, M. D.
    Krebs, M. G.
    Peguero, J.
    Clay, T. D.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    de Speville, B. Doger
    Bajaj, P.
    Mueller, C.
    Triebel, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S43 - S44
  • [20] Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
    Metcalf, R.
    Laban, S.
    Kristensen, C. A.
    Ciuleanu, T-E.
    Brana, I.
    Rivas, A. Soria
    Dieter, S. M.
    Bols, A.
    Forster, M. D.
    Covela, M. R.
    Christian, J.
    Vogl, F. D.
    Mueller, C.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 754 - 755
12345